NYSE: NVSNovartis Ag Stock
$89.49-0.35 (-0.39%)
Updated Jan 27, 2023
NVS Price
$89.49
Fair Value Price
N/A
Market Cap
$193.92B
52 Week Low
$74.09
52 Week High
$94.26
P/E
9.14x
P/B
3.19x
P/S
3.15x
PEG
N/A
Dividend Yield
3.75%
Revenue
$52.26B
Earnings
$21.80B
Gross Margin
70.6%
Operating Margin
46.7%
Profit Margin
41.7%
Debt to Equity
0.95
Operating Cash Flow
$14B
Beta
0.56
Next Earnings
Feb 1, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NVS Overview
Novartis AG manufactures prescription medications related to oncology, ophthalmology, neuroscience, immunology, respiratory, and cardio-metabolic medicine. Novartis AG is collaborating with Alnylam Pharmaceuticals to commercialize inclisiran. The company is also collaborating with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NVS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NVS is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NVS is good value based on its earnings relative to its share price (9.14x), compared to the US market average (23.59x)
P/E vs Market Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NVS due diligence checks available for Premium users.
Be the first to know about important NVS news, forecast changes, insider trades & much more!
NVS News
Valuation
NVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.14x
Industry
30.12x
Market
23.59x
NVS is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NVS is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
NVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.19x
Industry
5.24x
NVS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NVS's financial health
Profit margin
Revenue
$12.8B
Net Income
$1.6B
Profit Margin
12.2%
NVS's Earnings (EBIT) of $24.41B... subscribe to Premium to read more.
Interest Coverage Financials
NVS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$118.5B
Liabilities
$57.6B
Debt to equity
0.95
NVS's short-term assets ($36.95B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NVS's short-term assets ($36.95B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.7B
Investing
$5.2B
Financing
-$4.7B
NVS's operating cash flow ($14.01B)... subscribe to Premium to read more.
Debt Coverage Financials
NVS vs General Drug Manufacturer Stocks
Novartis Ag Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.